Regeneron Pharmaceuticals Aktie News

Regeneron Pharmaceuticals, Inc. delivered a strong Q3 earnings beat, driven by Dupixent growth, despite ongoing Eylea sales declines and manufacturing setbacks. REGN's future growth is anchored by Dupixent's expanding indications, a robust late-stage pipeline, and improving Libtayo performance, offsetting Eylea's decline. Management's financial discipline, $7B in manufacturing investments, and ...

Regeneron Pharmaceuticals, Inc. beat Q3 revenue and EPS expectations, and it appears investors are finally embracing the fact the Eylea franchise is no longer a growth product. Eylea franchise faces ongoing revenue declines, but market share losses have stabilized and regulatory issues for Eylea HD should be addressed in 2026. Dupixent collaboration profits with Sanofi are set to accelerate, su...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Leonard Schleifer - Co-Founder, President, CEO & Co-Chairman George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman Marion McCourt - Executive Vice President of Commercial ...

Regeneron stock advanced early Tuesday on better-than-expected third-quarter earnings despite a big tax hit.

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending its shares up 5.6% premarket.

TARRYTOWN, N.Y., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2025 and provided a business update.

Here is why we believe Regeneron Pharmaceuticals (REGN) stock is worthy of consideration as a value investment. It is presently trading nearly 38% lower than its one-year peak, and is also being traded at a price to sales multiple that is beneath the average for the past three years.

We purchased several new fund holdings across various sectors. Sempra has been shifting its strategic focus from its highly regulated California operations to its growing presence in Texas. Regeneron in our view has a strong balance sheet and a robust product pipeline.